LX 1031

Drug Profile

LX 1031

Alternative Names: LX1031

Latest Information Update: 13 Feb 2014

Price : $50

At a glance

  • Originator Lexicon Genetics
  • Developer Lexicon Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 13 Jan 2014 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
  • 01 May 2010 Pharmacodynamics data from a phase II trial in Irritable bowel syndrome presented at the Digestive Disease Week (DDW-2010)
  • 25 Nov 2009 Pharmacodynamics data from a clinical study in volunteers presented at the GASTRO 2009 (Joint Meeting) (GASTRO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top